Omidenepag Isopropyl

Omidenepag Isopropyl is a novel ocular hypotensive agent and certified reference standard developed for the treatment of glaucoma. As the active pharmaceutical ingredient in the ophthalmic solution marketed as Eybelis® in Japan, Omidenepag Isopropyl provides effective intraocular pressure lowering in patients with open-angle glaucoma. In pharmaceutical quality control contexts, Omidenepag Isopropyl serves as the primary reference standard for impurity profiling, analytical method development, and regulatory submissions. Omidenepag Isopropyl is recognized through multiple regulatory designations including INN and JAN, making it indispensable for quality control testing. The drug substance Omidenepag Isopropyl exhibits excellent stability when stored under recommended conditions, with its prodrug form ensuring optimal ocular bioavailability. Furthermore, Omidenepag Isopropyl functions as a selective EP2 receptor agonist—a distinct mechanism from latanoprost and other FP receptor agonists—demonstrating the therapeutic versatility of this well-characterized molecular scaffold.

Product Parameters

Why Cosperpharm?

When your ophthalmic pharmaceutical research or reference standard requirements demand uncompromising quality, Cosperpharm delivers Omidenepag Isopropyl with the analytical rigor, documentation depth, and supply flexibility that pharmaceutical customers have come to trust.

Purity that defines research success. The EP2 receptor binding activity of Omidenepag Isopropyl is exquisitely sensitive to impurities. Cosperpharm's analytical release protocol for Omidenepag Isopropyl includes HPLC purity verification (≥98%), appearance verification, and identity confirmation. Batch-specific chromatographic traceability ensures that your research or analytical method rests on a foundation of documented quality.

Documentation that supports your regulatory submission. As a reference standard for a recently approved novel ophthalmic drug, Omidenepag Isopropyl is essential for method validation and quality control programs. Every reference-grade shipment from Cosperpharm includes a Certificate of Analysis (COA) with batch-specific purity data and full characterization—structured for direct integration into your validation package.

Flexible supply across all research stages. Cosperpharm supplies Omidenepag Isopropyl from milligram quantities for analytical reference standard use to gram-scale batches for process development. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and analytical laboratories worldwide, with full customs documentation included.

Product Advantages

 Novel Non-Prostaglandin EP2 Agonist

Omidenepag Isopropyl represents a new class of ocular hypotensive agents that selectively target the EP2 receptor—a distinct mechanism from conventional prostaglandin FP receptor agonists. This unique mechanism offers an alternative for patients who may not respond adequately to latanoprost or other prostaglandin analogs.

 Prodrug Design for Enhanced Ocular Bioavailability

The isopropyl ester prodrug form of Omidenepag Isopropyl ensures optimal corneal penetration following topical ophthalmic administration. Following absorption, Omidenepag Isopropyl is rapidly hydrolyzed to the active metabolite omidenepag, which binds to EP2 receptors in the trabecular meshwork.

 Clinically Validated Efficacy

Omidenepag Isopropyl is approved in Japan as Eybelis® for the treatment of open-angle glaucoma, validating its safety and efficacy in clinical practice. The well-characterized pharmacological profile supports its use as a reference standard for glaucoma research.

 Dual-Use: API and Reference Standard

Cosperpharm supplies Omidenepag Isopropyl at high-purity grade for use in both research applications and as an analytical reference standard for method development and quality control programs.

FAQ

Q1: What is the mechanism of action of Omidenepag Isopropyl?

A: Omidenepag Isopropyl is a selective non-prostaglandin EP2 receptor agonist. Upon ocular administration, it is hydrolyzed to the active metabolite omidenepag, which binds to EP2 receptors in the trabecular meshwork, increasing aqueous humor outflow and reducing intraocular pressure.

Q2: What are the primary therapeutic indications for Omidenepag Isopropyl?

A: Omidenepag Isopropyl is indicated for the treatment of open-angle glaucoma and ocular hypertension. It is marketed as Eybelis® ophthalmic solution in Japan.

Contact Us

Connect with Cosperpharm for Omidenepag Isopropyl that delivers the purity, documentation, and supply reliability your research program requires.